Reprgramming
immunity
ReWire advances
immune modulation
Est. 2025
Orange bubbles macro photography
Fluorescent microscopy of cells
Blue fluid ripple pattern
Led by science and innovation

Restoring immune
balance with precision

At ReWire, we unite expertise in genomics, immunology, and gene therapy to tackle the root cause of autoimmune and inflammatory diseases. Our platform reprograms T cells in vivo with unmatched specificity.

Guided by world-class science from the University of Oxford, we are building curative therapies that go beyond symptom management, restoring the body's own immune regulation.

Compact design

Fully functional TRANCERs can be minimised to 400bp, making them ideal for size-constrained viral delivery vectors.

Bidirectional

Express two functional transcripts from one construct enabling all-in-one gene editing systems.

AI-compatible

Works with ML-designed synthetic enhancers or can use AI for enhancer feature improvements.

Our Patented Platform

The TRANCER Technology

Proven across mammalian cell lines, organoids, and in vivo in zebrafish and mice.
Patent number: PCT/GB2025/052425, publication 5th June 2026.

Ready to learn more?
Global autoimmune marketGlobal
Market
$0B
Population affected
0%
Proof-of-concept models
0+
In Vivo Immune Modulation

We deliver precision
in every construct

ReWire's TRANCER platform reprograms T cells directly in the body bypassing the costly, complex ex vivo manufacturing that limits current Treg therapies.

In vivo delivery

A simple injection delivers TRANCER constructs that reprogram T cells directly inside the patient's body.

Stable Tregs

Our reprogrammed regulatory T cells maintain stability, specificity, and long-term persistence.

Our People

Built at the University of Oxford's Weatherall Institute of Molecular Medicine

Dr. Elisa Barrow

Dr. Elisa Barrow

Co-Founder

Built the TRANCERS toolkit. Led all experimental validation proving platform robustness.

Adam F. El-Kadi

Adam F. El-Kadi

Head of Business Development

MSc Translational Health Sciences. Driving commercial strategy and fundraising.

Prof. Jim Hughes

Prof. Jim Hughes

Co-Founder

Oxford Professor of Genomics. Co-founder, Nucleome Therapeutics.

Prof. Thomas Milne

Prof. Thomas Milne

Co-Founder

Oxford Professor of Genomics. Co-founder, Dark Blue Therapeutics, acquired by Amgen.

Sample tubes arranged in a laboratory tray
Get in Touch

Have enquiries?
Reach out to us!

hello@rewiretx.com
Questions About ReWire

Frequently asked
questions

Here you'll find helpful answers about our platform, technology, pipeline, and partnership opportunities.

TRANCERs (TRanscriptionally Autonomous enhaNCERs) are a modular system that converts enhancers into cell-specific standalone promoters by coupling enhancer activity with transcript stabilisation and nuclear export mechanisms. TRANCERs retain enhancer-driven tissue specificity and are compact and resistant to silencing making them suitable and better than any other transgene therapy approach. More detailed information on the technology can currently be found as a pre-print.

The TRANCER platform is adaptable to gene therapies, gene editing and for research and synthetic biology applications.

ReWire is currently at the preclinical stage with TRANCERs under TRL-4. Specificity has been proven in vitro and in vivo in different indications. Currently we are working on relevant in vitro models. In the upcoming 12-24 months we will work on Treg modulation testing, animal efficacy studies and IND-enabling work.

Unlike current, costly and fragile ex vivo approaches that require extracting T-cells, processing, and reinfusing Tregs, ReWire delivers Treg-reprogramming constructs directly in vivo. Our TRANCERS technology offers the highest combination of Treg stability, cell-type specificity, and compact design in the competitive landscape.

Taking control of the human genome to cure disease